SCHEDULE 13G: Vestal Point Capital Discloses 9.9% Passive Stake in Applied Therapeutics, Inc.
Beneficial Ownership Report (Schedule 13G)
Vestal Point Capital, LP and Ryan Wilder have jointly filed a Schedule 13G, revealing a passive beneficial ownership of 9.9% in Applied Therapeutics, Inc.'s common stock.
Summary
- Vestal Point Capital, LP and Ryan Wilder, Chief Investment Officer and Managing Partner of Vestal Point Capital, LLC, have jointly reported beneficial ownership of 11,500,000 shares of Applied Therapeutics, Inc. common stock.
- This ownership represents 9.9% of the total outstanding common stock of Applied Therapeutics, Inc.
- The percentage is calculated based on 116,356,474 shares of common stock outstanding as of November 6, 2024, as reported in the company's Form 10-Q.
- The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Applied Therapeutics, Inc.
- Vestal Point Capital, LP is a Delaware limited partnership, and Ryan Wilder is a U.S. citizen.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a factual, regulatory disclosure of beneficial ownership, not an announcement of financial performance, strategic initiatives, or operational updates.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure of a significant passive investment in a publicly traded company within the biotechnology/pharmaceutical sector. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment itself.
Stakeholder Impact
- Shareholders: The disclosure of a new significant passive investor may be viewed positively by some shareholders as a vote of confidence, while others may monitor for any potential future changes in the investor's intent or stake.
Next Steps
- The reporting persons will be responsible for timely filing of subsequent amendments to this Schedule 13G if there are changes to their beneficial ownership or other required information.
Key Dates
| Date | Description |
|---|---|
| 2024-11-06 | Date as of which 116,356,474 shares of Common Stock were reported outstanding in the Company's Form 10-Q. |
| 2024-11-07 | Date Applied Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. |
| 2024-12-31 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G statement was signed and filed. |
Keywords
Applied Therapeutics Inc., Vestal Point Capital, Ryan Wilder, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Passive Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.